Cassava Sciences (NASDAQ: SAVA) has become a hot topic among traders and active market participants thanks to its recent ...

The share price of Cassava Sciences (NASDAQ:SAVA) increased from ~$1, to $10 between 2019 and 2020, tread water between 2020 and 2021, had increased in value to >$120 by August 2021, began 2022 ...

In March, pharmaceutical company Cassava Sciences made headlines for a report by the Food and Drug Administration (FDA) that cast doubt on the positive trial results of its novel Alzheimer’s ...

Cassava Sciences, Inc. reported $121.1m of cash and a net loss of $(97.2m) for the year 2023. The company's research and development expenses increased to $89.4m in 2023. Cassava's CEO remains ...

MarketWatch Sep 26, 2024, 10:49:00 PM ...

Shares of clinical-stage biotech Cassava Sciences (NASDAQ: SAVA) soared in 2021 for a couple of reasons. First, the company produced strong results in clinical studies for its potential therapy ...

Shares of Cassava Sciences (SAVA 2.83%) skyrocketed in the first half of 2021. The biotech's share price ran up 1,152% from the first of January to the end of June. Like most small biotech stocks ...

When it comes to a company like Cassava Sciences (NASDAQ: SAVA), which is working on therapies for Alzheimer's disease, that little rule of thumb feels like it could be truer than ever.

The stock's been a wild ride for investors all year, and it's dropped more than 50% in two days. What's going on, and why am I bullish? Editor's Note: This article was updated on Aug. 31 to ...

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication of new research ...

After surging from $7 per share to around $120 per share this year, Cassava Sciences (NASDAQ:SAVA) stock may not have room to make more “to the moon” moves higher. Source: Atthapon Raksthaput ...